Trump plans to reclassify marijuana. What does this mean for Delaware?

President Trump signed an executive order on Dec. 18 directing the attorney general to reclassify cannabis from Schedule I to Schedule III, a step that could eliminate application of Internal Revenue Code Section 280E—allowing licensed cannabis businesses to deduct ordinary business expenses—and ease FDA registration for research. The order does not legalize marijuana federally, will not change the noncompliant status of state-regulated markets, and leaves FDA approval, interstate commerce restrictions, federal penalties, drug-testing mandates and banking constraints intact until further federal action. Delaware, which legalized recreational and medical use and began retail sales on Aug. 1, 2025, is expected to see limited immediate operational change according to the state Marijuana Commissioner.

Analysis

Market structure: Re‑scheduling to Schedule III materially raises the floor for the industry by removing 280E tax shackles and enabling easier FDA/DEA research access — model a 10–25% potential net‑margin uplift for compliant MSOs/retailers within 12–24 months assuming IRS implements relief. Winners: regulated U.S. MSOs, cannabis-focused REITs (IIPR), payment/ancillary providers and ETFs (MJ). Losers: illicit sellers if enforcement increases, small inefficient producers and heavily dilutive Canadian LPs facing FX and oversupply pressures.

Risk assessment: Key tail risks are DEA/administrative delays, adverse IRS transitional rules, banking/FDIC refusals and state tax rebalancing — any single adverse action could erase the valuation rerating. Near term (days–weeks) expect little market movement until formal notices; short term (1–6 months) is dominated by IRS/DEA guidance and bank policy; long term (12–36 months) is structural (margin expansion, M&A). Hidden dependency: tax relief only materializes with specific IRS rulings and clarifying litigation risk.

Trade implications: Preferred plays are differentiated, regulated cashflow and ancillary exposure over levered cultivation names. Tactical: overweight MJ ETF and IIPR, use tight hedged option structures on single‑name MSOs to capture binary regulatory wins while limiting downside. Catalyst triggers (IRS guidance, bank FDIC memos, DEA final rule) should be used to scale positions.

Contrarian angles: Consensus assumes rapid consumer demand growth; risk is supply overshoot (hemp 2019 parallel) that compresses wholesale prices and forces consolidation. Market may underprice REITs/ancillaries which get durable income even if retail margins oscillate; conversely, Canadian LPs still face structural dilution. Unintended consequence: state tax hikes to capture new profit could blunt household demand and cap upside.

Key Decisions for Investors

• Establish a 2–3% portfolio long in the cannabis ETF MJ within 2–6 weeks to capture sector rerating; trim/exit at +40–60% or if DEA final rule delay >180 days.
• Allocate 1–2% to Innovative Industrial Properties (IIPR) buy-and-hold for 3–12 months to capture stable cash yield and capital appreciation; set a protective stop-loss at 12% and target total return 10–20% in 12 months.
• Put on a pair trade: long 2% MJ ETF / short 1–1.5% Canopy Growth (CGC) for a 6–12 month horizon — rationale: U.S. regulatory clarity favors U.S. market/ancillaries over oversupplied Canadian LPs; unwind if spread narrows by >15%.
• Deploy a limited-risk options sleeve: buy 6–9 month call spreads (0.5–1% portfolio risk) on TLRY with strikes ~30–50% OTM to leverage upside if IRS/DEA guidance arrives within 90 days; cap premium and avoid naked exposure.
• Monitor three binary triggers (IRS 280E guidance, DEA rescheduling publication, FDIC/bank policy memo) on a 30/90/120‑day cadence and increase sector exposure by up to +2% each time a positive trigger is confirmed.